Key catalysts ahead: Phase 3 initiation details, regulatory interactions, and any partnership interest in the PWS program.
RYTM drugs
RYTM drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 15 $89.70entry
- T+1 · 5mo ago +0.02%α +0.62% · $89.72
- T+5 · 5mo ago +13.03%α +14.42% · $101.39
- T+20 · 4mo ago +19.83%α +20.58% · $107.49
- T+60 · 2mo ago +12.66%α +11.66% · $101.06
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Rhythm Pharmaceuticals reported positive Phase 2 data for setmelanotide in Prader-Willi syndrome at ENDO 2026, showing clinically meaningful BMI reductions, fat mass loss with lean mass preservation, and improvements in hyperphagia and anxiety. The results de-risk the path to Phase 3 development in a large unmet-need population, reinforcing the MC4R agonism thesis.
Key Facts
- Phase 2 trial of setmelanotide in PWS (N=17) showed -3.06% mean BMI reduction at Month 6; 8 of 10 patients with moderate-to-severe hyperphagia achieved ≥7-point HQ-CT improvement.
- DEXA scans (N=16) showed +0.74% mean lean mass gain and -4.19% mean fat mass loss; 6 of 9 adults had >5% fat mass reduction.
- 10 of 15 patients with baseline PADQ >11 achieved ≥11-point improvement in anxiousness/distress behaviors.
- Safety profile consistent with established setmelanotide data; no new safety signals.
- Company advancing to Phase 3 in PWS, a condition affecting ~400,000 people globally with limited effective treatments.
Financial Impact
No financial data provided in the press release; Phase 2 data de-risks a potential $500M+ peak sales opportunity in PWS (est. 8,500-12,750 US patients with hyperphagia/obesity), but no revenue guidance or deal value disclosed.
Risk Factors
- Phase 3 trials may fail to replicate these results in a larger, more diverse population.
- PWS is a complex syndrome; regulatory path for hyperphagia endpoint is not fully established.
- Competition from other MC4R agonists or alternative therapies could limit commercial uptake.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3311380 |
Track record
26 reports on RYTM
8 of 13 bullish or bearish reports moved the stock their way by T+5. Best: +32.06% at T+60 after the May 1, 2026 report. 10 of 13 went positive at some point.
Filters
- Nov 16, 2026today Press Release Bullish 5/10 Entry $107.48 Now $107.48 +0.00% settles Nov 24
- Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $110.68 to $112.16 Now $107.48 −2.89% ▲ +1.34% +2.25% vs SPY
- Nov 4, 202612d ago Press Release Bullish 5/10 Entry $110.68 to $112.16 Now $107.48 −2.89% ▲ +1.34% +2.25% vs SPY
- Nov 3, 202613d ago 8-K Bullish 6/10 No price data
- Nov 3, 202613d ago Press Release Bullish 6/10 Entry $86.44 to $113.95 Now $107.48 +24.34% ▲ +31.83% +32.41% vs SPY
- Nov 2, 202613d ago Press Release Neutral 5/10 Entry $86.44 to $113.95 Now $107.48 +24.34% ▲ +31.83% +32.41% vs SPY
- Oct 13, 20264w ago Press Release Bullish 6/10 Entry $86.71 to $88.62 Now $107.48 +23.95% ▲ +2.20% +1.75% vs SPY
- Oct 13, 20264w ago SC 13G Neutral 3/10 Entry $86.61 to $90.20 Now $107.48 +24.10% ▲ +4.14% +5.30% vs SPY
- Sep 14, 20269w ago 144 Bearish 5/10 Entry $96.77 to $99.27 Now $107.48 −11.07% ▼ −2.58% −0.47% vs SPY
- Aug 17, 202613w ago Insider Cluster Bearish 6/10 Entry $115.25 to $113.35 Now $107.48 +6.74% ▲ +1.65% +1.45% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers